The Sunlight on the CMTA series has run nine posts since October 9 on the US-based Charcot-Marie-Tooth Association: how it sells CMT, who decides where donor money goes, and what it doesn’t disclose. Here’s what has already been published, what has changed since then, and what’s coming next.
New reference pages: CMT Charities Around the World maps the CMT patient charities with their latest budgets, in their own currencies, and links each figure to its source. Who’s Who in American CMT Fundraising and Research lines up the roles held by the people behind the US charities since 2004, and shows where they overlap with companies, universities, and advisory boards.
What Has Been Published
Who Decides Where the Money Goes
- Who Is Behind the CMTA? (October 10). In 2025, half the money the CMTA granted for US research went to projects led by its own advisers, or to a company one of them helps run. This post looks into the CMTA’s staff, boards, tax returns, grants, and conflict rules, from its own pages and IRS filings.
- Shark Tooth: The CMTA’s Stake in a Board Member’s Biotech (October 10). In 2025 the CMTA held a $248,763 stake in a for-profit CMT1A company founded and owned by one of its own directors, David Apple, paid for with donations to the CMTA earmarked for Shark Tooth.
- Tom Dubensky, the CMTA’s Venture Arm, and Shark Tooth (November 17). A longtime CMTA director spoke for the charity when it began investing in biotech companies, and he is listed as an adviser to Shark Tooth. This post covers what the record shows about Tom Dubensky’s roles, and what it doesn’t.
Research, Rights, and the Rules for Trials
- Canada’s CMT1A Research Partnership: Who Funds It, and Who Gets the Rights? (October 28). The National Research Council of Canada, the CMTA, and Shark Tooth are working together on a new way to deliver a CMT1A treatment. Who is paying for it, who will own the results, and what will Canada get back?
- Who Writes the Rules for CMT Drug Trials? (October 29). The first framework for designing CMT drug trials was written by patient charities, clinicians, and drug companies, including two companies the CMTA has money in. The published paper carries no public conflict-of-interest statement. This post evaluates the paper and the transprency issue.
- One Patient, One Drug—and a Possible Voucher (November 3). Drugs made for a single patient are one of the most hopeful ideas in rare-disease medicine. This post asks who pays for them, who profits, and can patient and commercial interests truly align?
How the CMTA Presents CMT
- The Sloth’s Taxonomy: A Review of “Experts in CMT” (October 10). Kenny Raymond’s “Experts in CMT” website and books stretch a contested way of classifying CMT and bill him as an expert, though he has no clinical training in genetics. The CMTA hired him in 2023, after he had moderated its Facebook group and sat on its non-clinical Advisory Board. The only endorsement on his second book comes from the CMTA’s chief research officer. His gene guide counts giant axonal neuropathy (GAN) as CMT, citing a CMTA “GAN initiative” that, as far as the record shows, was one sentence saying the charity was following an NIH trial. Neither Raymond’s guide nor his website says he works for the CMTA. Both the CMTA and the Hereditary Neuropathy Foundation still give the guide away on their websites. A charity’s marketing communications staff should not be writing clinical reference guides. This post reviews the book and the undisclosed relationships behind it.
- Barbies and Warriors: How the CMTA Sells CMT (October 10). “CMT Barbie,” “CMT warriors,” a CBD sponsor, an Amazon store that pays a commission, and an unproven oxygen therapy that can cost thousands — this post examines how the disease is marketed to people who have it and prospective donors, in the CMTA’s own words.
- How the CMTA Mishandles Moderation and Its Facebook Community (October 9). How I was removed from the CMTA’s Facebook group a decade ago with no appeal because I blocked a moderator who abusively trolled my personal page, how the CMTA kept emailing me for years after promising to delete my records, and what Canadian and US privacy and anti-spam laws say about it. This post explains the pattern of irresponsibility and abuse that led me to probe deeper and eventually produce this series of investigations, after years of reflection and research.
What Has Changed Since Publication
I asked the people and organizations covered in these posts for comment before publishing. Their replies have been added to the posts, and I have corrected my own mistakes as they came up. In brief:
- David Apple said he owns all of Shark Tooth’s shares for now, that he stepped aside from every CMTA decision about the company, and that neither he nor Shark Tooth is paid with CMTA money. After I pointed to state records, he corrected the date he had given for incorporating the company. He then declined further questions.
- The CMTA’s chief executive, Sue Bruhn, did not answer my questions one by one. She described conflict-of-interest practices that go beyond what the CMTA’s published policy requires, but she declined to specify them or share written source documents.
- The National Research Council confirmed that the CMTA and Shark Tooth fund the CMT1A project and that NRC contributes no money. It declined to share the agreement’s terms.
- Shark Tooth’s website changed Tom Dubensky’s label from “Board of CMTA” to “Former CMTA Board Member” after I asked about his role. Archived copies of the page show it before and after.
- Tom Dubensky had not replied by my November 13 deadline. His LinkedIn profile, which I read on November 17, lists him as a CMTA board member from June 2016 to March 2026, and as ImmuneSensor’s president and CEO until September 2026. It does not mention Shark Tooth.
- The Hereditary Neuropathy Foundation hosts Raymond’s gene guide on its own website, in a file uploaded in April 2023 and named “HNF-Website.” I compared the two copies page by page, and the text is identical. I added this to my review of Raymond’s book on November 19.
- Corrections: every correction, clarification, and update to these posts is listed, with dates, on the Updates and Corrections page.
What Is Still to Come
The series started with the CMTA, but its questions apply to every organization that speaks for people with CMT or spends (often their) money in their name. Who makes the decisions? Who pays? Who benefits? Each organization will be held to the same standard and given the same chance to respond. That means the other CMT charities (the Hereditary Neuropathy Foundation, the CMT Research Foundation, and Cure CMT), the neuromuscular charities that fund CMT work (the Muscular Dystrophy Association and Muscular Dystrophy Canada), the research networks and journals that set the field’s direction, the companies charities invest in, and the public bodies in Canada and the US whose money and labs are part of the story. I will also be expanding my scope to the international scene for CMT research and its funding.
- The CMTA’s four biotech bets. The CMTA now holds stakes in four private companies. One of them, EverTree Bio, is also backed by a second CMT charity run by the CMTA’s former chief executive.
- Giant axonal neuropathy. The CMTA’s Types of CMT page didn’t list GAN in May 2021. By August it did, four months after Taysha Gene Therapies bought the rights to a GAN gene therapy. That October, Taysha announced free GAN testing, working with the Hereditary Neuropathy Foundation and the CMTA’s Centers of Excellence to find patients. Taysha dropped the program in 2023. GAN is still on the CMTA’s list.
- Who owns “Cure CMT”? Cure CMT, the charity Pat Livney started after leaving the CMTA, is currently suing the Hereditary Neuropathy Foundation in federal court in Chicago over the name and HNF’s curecmt.org website. Livney’s trademark is on the US Patent and Trademark Office’s Supplemental Register, for names it finds too descriptive for the main one. HNF hasn’t yet answered the complaint.
- The CMTA’s advisers. What its advisory boards do, what the tax rules don’t require it to disclose, and what its grants to advisers’ institutions add up to.
- Who pays for CMT research now. The CMTA took over funding the field’s main clinical research network just as US government pulled back science funding.
- Donor data. In 2021, according to the CMTA, a departing fundraiser downloaded its list of about 43,000 donors, in large part people with CMT and their families, and she took it to a new rival charity, the CMT Research Foundation (CMTRF), that she co-founded with Pat Livney. The CMTA called it a “data breach,” sued, and dropped the case months later, saying it had recovered the data. We’ll look at how CMT charities have handled donors’ information, starting there, and what they’re doing today in a context of escalating cybersecurity threats and failures.
- Follow the Money: CMT Charities Side by Side. The CMTA, the Hereditary Neuropathy Foundation (HNF), the CMT Research Foundation, and Muscular Dystrophy Canada compared from their own tax filings: revenue, programme spending, and research grants. Each charity will be asked for comment before this investigation runs.
- And the other side. Why I watch the CMT charities, and four lesser known, model groups doing CMT research in the open.
- The NRC agreement. NRC would not share the terms of its agreement with the CMTA and Shark Tooth. I am seeking them under the Access to Information Act and will report what is released.
- The CMTA’s conflict records. On October 15 I asked the CMTA for its written conflict-of-interest policies and for the records of who approved the Shark Tooth investment and the NRC funding. As of November 18, it has not replied.
- The JPNS’s answer. On October 13 I asked the editors of the Journal of the Peripheral Nervous System whether the authors of the CMT trial-design paper disclosed their financial ties, and whether editors with CMTA connections stepped aside from its review. As of November 18, they have not replied.
- Late replies. Any answer that arrives after a post has run will be added to that post and noted on the Updates and Corrections page.
If you’re in Canada and looking for help with CMT, see CMT Research and Support Organizations in Canada That Are Actually Canadian.

Leave a Reply